EZH2 and prostate carcinoma: In such a context, the catalytic component of PRC2, the methyltransferase enhancer of Zeste homolog 2 (EZH2), another HSP90 client protein, is upregulated in several tumors, including breast and prostate cancers, and its overexpression correlates with a poor prognosis [110,111].